APLS Q3 2024 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$197M+78.3% YoY

Gross Profit

$163M83.0% margin

Operating Income

-$47M-24.0% margin

Net Income

-$57M-29.2% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

-1.4%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

$34M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$902M

Total Liabilities

$665M

Stockholders' Equity

$237M

Cash & Equivalents

$397M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$197M	$110M	+78.3%
Gross Profit	$163M	$88M	+85.6%
Operating Income	-$47M	-$137M	+65.5%
Net Income	-$57M	-$140M	+59.0%

Revenue Segments

Product

$177M90%

Licensing And Other Revenue

$20M10%